Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biofrontera (BFRI) EBITDA (2020 - 2025)

Historic EBITDA for Biofrontera (BFRI) over the last 6 years, with Q3 2025 value amounting to -$6.3 million.

  • Biofrontera's EBITDA fell 2657.26% to -$6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 902.24%. This contributed to the annual value of -$17.2 million for FY2024, which is 2410.81% up from last year.
  • According to the latest figures from Q3 2025, Biofrontera's EBITDA is -$6.3 million, which was down 2657.26% from -$5.1 million recorded in Q2 2025.
  • Biofrontera's EBITDA's 5-year high stood at -$1.7 million during Q4 2024, with a 5-year trough of -$16.1 million in Q3 2021.
  • Its 5-year average for EBITDA is -$5.2 million, with a median of -$5.0 million in 2024.
  • As far as peak fluctuations go, Biofrontera's EBITDA crashed by 58707.34% in 2021, and later soared by 7740.45% in 2022.
  • Biofrontera's EBITDA (Quarter) stood at -$1.9 million in 2021, then tumbled by 196.86% to -$5.6 million in 2022, then soared by 30.75% to -$3.9 million in 2023, then surged by 55.71% to -$1.7 million in 2024, then crashed by 266.71% to -$6.3 million in 2025.
  • Its EBITDA stands at -$6.3 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$4.5 million for Q1 2025.